{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:57Z","timestamp":1747181097589,"version":"3.40.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Botulinum toxin type A injection is widely used treatment option for the treatment of upper limb spasticity in stroke patients. The purpose of this study was to explore the safety and efficacy of MT10107, a new botulinum toxin type A, in patients with post-stroke upper limb spasticity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A prospective, randomized, double-blind, active drug-controlled, multi-center, phase I clinical trial. Thirty patients with post-stroke upper limb spasticity were received either MT10107 or onabotulinumtoxinA. Primary endpoint was change of modified Ashworth scale (MAS) score for wrist flexor from baseline to week 4. The secondary endpoints were changes of MAS scores for elbow and finger flexors, response rate, Disability Assessment Scale (DAS), and global assessment of treatment. The safety endpoints such as adverse events, vital signs, physical examination, and laboratory test were evaluated. The outcome measures were evaluated from baseline to week 4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The primary endpoints were \u22121.07\u2009\u00b1\u20090.70 and \u22121.23\u2009\u00b1\u20090.56 for the MT10107 and onabotulinumtoxinA groups, respectively. The intergroup difference of change between the 2 groups was 0.17 (95% confidence interval \u22120.31 to 0.64, <jats:italic toggle=\"yes\">P<\/jats:italic> = .5769). In secondary endpoints, both groups showed a significant improvement in both MAS and DAS. There was no significant between-group difference in all secondary endpoints and safety measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The safety and efficacy of MT10107 showed no significant difference compared to onabotulinumtoxinA in post-stroke upper limb spasticity treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031367","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T19:13:09Z","timestamp":1667848389000},"page":"e31367","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment: A phase I randomized controlled trial"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9900-0961","authenticated-orcid":false,"given":"Junekyung","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-7225","authenticated-orcid":false,"given":"Min Ho","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Uk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deog Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Jong","family":"Paik","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"8329306","DOI":"10.1155\/2019\/8329306","article-title":"Efficacy and safety of botulinum toxin type A for limb spasticity after stroke: a meta-analysis of randomized controlled trials","volume":"2019","author":"Sun","year":"2019","journal-title":"Biomed Res Int"},{"key":"R2-20250504","first-page":"32","article-title":"Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens","volume":"26","author":"Slawek","year":"2005","journal-title":"Clin Trial"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Kanovsk\u00fd","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2013.11.022","article-title":"Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German\u2013Austrian open-label post-marketing surveillance prospective study","volume":"337","author":"Jost","year":"2014","journal-title":"J Neurol Sci"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e0128633","DOI":"10.1371\/journal.pone.0128633","article-title":"Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial","volume":"10","author":"Seo","year":"2015","journal-title":"PLoS One"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2015.07.028","article-title":"Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial","volume":"357","author":"Nam","year":"2015","journal-title":"J Neurol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0269215516689331","article-title":"Safety and efficacy of letibotulinumtoxinA (BOTULAX\u00ae) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial","volume":"31","author":"Do","year":"2017","journal-title":"Clin Rehabil"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.hcl.2018.06.001","article-title":"Common etiologies of upper extremity spasticity","volume":"34","author":"Angulo-Parker","year":"2018","journal-title":"Hand Clin"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3121\/cmr.2007.716","article-title":"Botulinum toxin in poststroke spasticity","volume":"5","author":"Ozcakir","year":"2007","journal-title":"Clin Med Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12325-018-0833-7","article-title":"Incobotulinumtoxina efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study","volume":"36","author":"Marciniak","year":"2019","journal-title":"Adv Ther"},{"key":"R11-20250504","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/toxins8010004","article-title":"Efficacy and safety of a new botulinum toxin type a free of complexing proteins","volume":"8","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/archopht.121.11.1661-a","article-title":"Botulinum toxin and human serum albumin","volume":"121","author":"Malhotra","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1097\/00002480-200011000-00040","article-title":"Prion disease and medical devices","volume":"46","author":"Antloga","year":"2000","journal-title":"ASAIO J"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter-and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"R17-20250504","first-page":"395","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke","volume":"347","author":"Brashear","year":"2002","journal-title":"Med J Malaysia"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1191\/026921599677595404","article-title":"A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity","volume":"13","author":"Pandyan","year":"1999","journal-title":"Clin Rehabil"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1468-1331.2001.00277.x","article-title":"A randomized, double\u2010blind, placebo\u2010controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke","volume":"8","author":"Bakheit","year":"2001","journal-title":"Eur J Neurol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","article-title":"Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study","volume":"80","author":"Simpson","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R21-20250504","first-page":"319","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke","volume":"62","author":"Jahangir","year":"2007","journal-title":"Med J Malaysia"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke","volume":"85","author":"Childers","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/01.STR.31.10.2402","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke","volume":"31","author":"Bakheit","year":"2000","journal-title":"Stroke"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1191\/026921598668275996","article-title":"Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Hesse","year":"1998","journal-title":"Clin Rehabil"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Ka\u0148ovsk\u00fd","year":"2011","journal-title":"J Rehabil Med"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mus.24776","article-title":"Randomized, placebo\u2010controlled trial of incobotulinumtoxina for upper\u2010limb post\u2010stroke spasticity","volume":"53","author":"Elovic","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:19:15Z","timestamp":1746328755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":27,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031367","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}